When was romidepsin first approved by the FDA?

Romidepsin (Istodax®) was first FDA-approved on October 29, 2009, for cutaneous T-cell lymphoma in patients with prior systemic therapy. It received a second indication approval for peripheral T-cell lymphoma in November 2011. The approvals were based on Phase II trial data demonstrating response rates of 34% in CTCL and 38% in PTCL.

What is the clinical evidence supporting romidepsin's approval?

[Pivotal Phase II trials (GPI-04-001 and GPI-05-001) demonstrated durable responses in relapsed/refractory T-cell lymphomas](https://pubmed.ncbi.nlm.nih.gov/19564536), with manageable safety profiles. Over 99 additional clinical trials have since investigated romidepsin in combination therapies and expanded indications, reinforcing its role in oncology.

Is romidepsin approved outside the United States?

Yes. The EMA approved romidepsin in 2012 for CTCL and PTCL, and Health Canada approved it in 2013. Romidepsin holds regulatory authorization in major markets including the US, EU, Canada, and others, with consistent indications and safety profiles across regions.

What is Orphan Drug Designation and how did it apply to romidepsin?

Orphan Drug Designation is a regulatory status granted to drugs for rare diseases affecting fewer than 200,000 people in the US. Romidepsin received this designation in 2006 for CTCL, providing tax incentives, faster review, and seven-year market exclusivity—critical support for developing therapies in small patient populations.

Are there ongoing clinical trials with romidepsin?

[Over 99 registered clinical trials involving romidepsin are active or recently completed on ClinicalTrials.gov](https://clinicaltrials.gov/search?q=romidepsin), exploring combination therapies (with azacitidine, brentuximab vedotin, and checkpoint inhibitors), new malignancy indications, and biomarker-driven patient selection strategies.

Romidepsin Regulatory History: FDA Approval to Current Status

Romidepsin is an FDA-approved HDAC inhibitor with a fascinating regulatory trajectory spanning over two decades. Originally discovered as a natural compound in bacterial cultures, it emerged from the laboratory to become a cornerstone therapy for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). The path to approval involved extensive clinical investigation across 99+ registered trials, multi-agency international review, and a landmark breakthrough designation that accelerated its clinical development. Today, romidepsin holds full regulatory status in the US, EU, and Canada, with ongoing research exploring its potential in combination therapies and additional malignancies.

Early Discovery and Development (1990s–Early 2000s)

Romidepsin's story begins with a serendipitous discovery. In the 1990s, researchers isolated the compound from Chromobacterium violaceum, a soil bacterium. The molecule's structure—a cyclic depsipeptide—immediately caught the attention of cancer researchers investigating histone deacetylase (HDAC) inhibition. Unlike broad-spectrum chemotherapy, HDAC inhibitors work by altering the way cells regulate gene expression, creating a novel mechanism for forcing cancer cells toward death.

Early preclinical work demonstrated romidepsin's potency in laboratory models of T-cell lymphomas. These findings were compelling enough to justify advancement into human trials, though the development path would be longer and more complex than initially anticipated.

Preclinical and Early Clinical Phase (2000–2006)

Between 2000 and 2006, romidepsin underwent rigorous preclinical characterization followed by Phase I dose-escalation studies. Researchers needed to establish not only efficacy but also a tolerable dose and safety profile. Early-phase trial data revealed that the compound had significant activity against T-cell lymphomas, but also that it carried notable toxicities requiring careful patient monitoring.

During this period, the compound was developed under the working names FK228 (its original designation) and later commercialized as Istodax®. Key early trials established the foundation for later registration studies.

Phase II Breakthrough and Orphan Drug Designation (2005–2008)

A pivotal moment came in 2005 when Phase II trial results were presented, demonstrating a response rate of approximately 34% in relapsed or refractory CTCL patients. This was remarkable—existing therapies for advanced CTCL offered responses in the 10–25% range.

Recognizing the unmet medical need in rare T-cell lymphomas, the FDA granted Orphan Drug Designation to romidepsin for CTCL in 2006. This designation provided regulatory incentives including tax credits for clinical trial costs, seven-year market exclusivity post-approval, and priority review pathways—critical support for developing therapies for small patient populations.

FDA Approval for Cutaneous T-Cell Lymphoma (October 2009)

On October 29, 2009, the FDA approved romidepsin (Istodax®) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received prior systemic therapy. This approval was based on data from a pivotal Phase II trial (GPI-04-001) that enrolled 96 patients with CTCL. The trial demonstrated durable responses and manageable toxicity, with the most common adverse events being nausea, vomiting, and myelosuppression.

This was a significant milestone—romidepsin became the first new HDAC inhibitor approved by the FDA for a hematologic malignancy, validating the entire class of HDAC inhibitors as viable cancer therapeutics.

Expanded Development in Peripheral T-Cell Lymphoma (2009–2014)

Building on its CTCL success, romidepsin entered development for peripheral T-cell lymphomas (PTCL), a broader category of rare T-cell malignancies. Multiple Phase II studies were conducted between 2010 and 2013, each enrolling patients with various PTCL subtypes.

A landmark Phase II trial (GPI-05-001) enrolled 131 patients and demonstrated response rates of 38% in relapsed/refractory PTCL. These results were presented at major hematology conferences and published in high-impact journals, strengthening the regulatory dossier.

The data also revealed important pharmacodynamic insights: romidepsin's mechanism involved inducing histone acetylation, which led to gene re-expression and forced cancer cells into apoptosis (programmed death).

FDA Approval for Peripheral T-Cell Lymphoma (November 2011)

On November 23, 2011, the FDA granted approval for romidepsin to treat peripheral T-cell lymphomas (PTCL) in patients who have received at least one prior therapy. This expanded the addressable patient population and solidified romidepsin's position as a cornerstone therapy for rare T-cell malignancies.

The approval triggered widespread uptake in specialized cancer centers, particularly those treating lymphoma. Insurance coverage was generally favorable due to the strong clinical evidence and unmet medical need.

International Regulatory Approvals (2012–2014)

Following FDA approval, romidepsin entered regulatory review in other major markets:

European Medicines Agency (EMA): The EMA approved romidepsin (Istodax®) in 2012 for CTCL and PTCL, following a centralized procedure review. EMA approval was based on the same Phase II data as the FDA, with European advisory committees noting the favorable benefit-risk profile in patients with limited alternatives.
Health Canada: Canada approved romidepsin in 2013, recognizing its novel mechanism and strong efficacy data in rare T-cell lymphomas.

These international approvals reflected global recognition of romidepsin's value and facilitated access for patients outside the US.

Ongoing Clinical Research and Combination Studies (2014–Present)

Since initial approvals, the field has shifted toward investigating romidepsin in combination with other agents. As of 2024, there are over 99 registered clinical trials involving romidepsin on ClinicalTrials.gov, spanning:

Combination therapies: Romidepsin + azacitidine, romidepsin + brentuximab vedotin, and other novel pairings designed to enhance anti-tumor activity.
New indications: Investigational studies in Hodgkin lymphoma, other hematologic malignancies, and select solid tumors.
Mechanism studies: Research into patient selection biomarkers and predictors of response.

A notable example is a Phase II trial combining romidepsin with azacitidine in PTCL patients, which showed improved response rates compared to single-agent data from historical controls.

Regulatory Framework and Current Status

Today, romidepsin holds the following regulatory designations:

FDA Approval: Approved for CTCL (relapsed/refractory) and PTCL (relapsed/refractory) under accelerated approval and traditional pathways.
EMA Authorization: Authorized in the EU with the same indications.
Health Canada Approval: Licensed for both CTCL and PTCL.
Orphan Drug Status: Maintains orphan designation in the US and EU, ensuring continued market exclusivity and research support.

The drug is manufactured by Celgene Corporation (now part of Bristol Myers Squibb) and distributed globally as Istodax® under various trade names.

Key Regulatory Learnings and Impact

Romidepsin's regulatory journey illustrates several important principles in modern drug development:

Orphan Drug Excellence: The orphan drug framework enabled efficient development for a rare indication, reducing time and cost by focusing on a well-defined population.
Mechanism-Driven Approval: Strong mechanistic rationale (HDAC inhibition) and early biomarker insights supported regulatory confidence, even in rare populations.
Durability of Efficacy: Unlike some cancer drugs that show brief responses, romidepsin demonstrated durable remissions, with some patients maintaining response for years—a critical factor in regulatory decision-making.
Safety Characterization: Transparent, comprehensive safety reporting in clinical trials built trust with regulators and clinicians. Adverse events are well-characterized, allowing for informed patient selection and monitoring strategies.

Current Research Horizon

The regulatory landscape for romidepsin continues to evolve. Recent interest has focused on:

Combination regimens with checkpoint inhibitors (such as nivolumab in T-cell lymphomas).
Induction therapy prior to allogeneic stem-cell transplantation in PTCL.
Novel formulations and delivery methods to improve tolerability.

These efforts suggest that romidepsin's regulatory status may expand further, with potential new indications and labeling updates in the coming years.

Comparison with Related Compounds

Romidepsin is one of several approved HDAC inhibitors. For context:

Vorinostat (Zolinza®): Approved for CTCL (2006); oral formulation; broader indication but narrower FDA approval.
Belinostat (Beleodaq®): Approved for PTCL (2014); intravenous; similar mechanism to romidepsin.
Panobinostat (Farydak®): Approved for multiple myeloma (2015); oral; different patient population.

Romidepsin remains the most widely used HDAC inhibitor in hematologic malignancies and has the broadest regulatory approval for T-cell lymphomas.

Future Directions and Regulatory Outlook

As research continues, romidepsin's regulatory status is likely to evolve. Potential areas for expansion include:

Approval in earlier lines of therapy (first-line CTCL/PTCL).
New combinations with emerging immunotherapies.
Expanded use in solid tumors, pending clinical evidence.

Regulatory agencies are watching closely as new trial data emerges, particularly regarding long-term outcomes and quality-of-life improvements in treated populations.

Romidepsin Regulatory History: From Discovery to Global Approval